George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMP.L Regulatory News (AMP)

  • There is currently no data for AMP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director dealing

10 Jan 2018 17:09

RNS Number : 5371B
Amphion Innovations PLC
10 January 2018
 

 

AMPHION INNOVATIONS PLC

 ("Amphion" or "the Company")

 

Directors' Dealings

London and New York, 10 January 2018 - Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, announces that on 5 January 2018 it granted options over ordinary shares in the Company ("Options") to certain of its directors as follows:

Director

Amount

Strike Price

Vesting

Richard Mansell-Jones

563,000

1.94 pence

Over one year starting as of 1 August 2017

Miroslaw Izienicki

375,000

1.94 pence

Over one year starting as of 1 August 2017

 

All Options commence vesting backdated from 1 August 2017.

 

The strike price is based on the closing price on 4 January 2018, and the Options are exercisable on the date of vesting. Authority for the allotment of ordinary shares under the Share Option Scheme was approved as a part of the Company's Annual General Meeting.

 

In addition to the above Options allocation, the Company has issued 799,562 ordinary shares in the Company ("New Ordinary Shares"), representing 0.38% of the enlarged issued share capital, to certain of its Board members (current and former) in payment of directors' fees due them. The issue of Ordinary Shares is calculated based on the closing mid-market price for the five days leading up to the close on 4 January 2018. Following this issue the current directors' shareholdings in the Company are as follows:

 

Director

Number of New Ordinary Shares

Total Shareholding

Percentage ofVoting Rights

Miroslaw Izienicki

193,791

795,280

0.379%

Richard Mansell-Jones

558,896

4,344,426

2.069%

Gerard Moufflet (former director)

46,875

1,320,833

0.629%

Admission of the 799,562 New Ordinary Shares, ranking pari passu with the existing ordinary shares, to trading on AIM is expected on 17 January 2018. Following the issue and allotment of the New Ordinary Shares, the total issued share capital of the Company will increase to 209,975,450 ordinary shares with each share holding one voting right. This figure may be used by shareholders in the Company as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Richard Mansell-Jones

2

Reason for the notification

a)

Position/status

Chairman and PDMR

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Amphion Innovations plc

b)

LEI

213800M7MTE2W2P6C104

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Ordinary Shares

b)

Nature of the transaction

Richard Mansell-Jones has received new Ordinary Shares in lieu of fees

c)

Price(s) and volume(s)

558,896 Ordinary Shares

d)

Aggregated information

- Aggregated volume

- Price

 

N/A (Single transaction)

e)

Date of the transaction

5 January 2018

f)

Place of the transaction

Outside a trading venue

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Miroslaw Izienicki

2

Reason for the notification

a)

Position/status

Non-executive Director and PDMR

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Amphion Innovations plc

b)

LEI

213800M7MTE2W2P6C104

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Ordinary Shares

b)

Nature of the transaction

Miroslaw Izienicki has received new Ordinary Shares in lieu of fees

c)

Price(s) and volume(s)

193,791 Ordinary Shares

d)

Aggregated information

- Aggregated volume

- Price

 

N/A (Single transaction)

e)

Date of the transaction

5 January 2018

f)

Place of the transaction

Outside a trading venue

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Richard Mansell-Jones

2

Reason for the notification

a)

Position/status

Chairman and PDMR

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Amphion Innovations plc

b)

LEI

213800M7MTE2W2P6C104

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Options to acquire Ordinary Shares

b)

Nature of the transaction

Grant of options to acquire Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

1.94p

563,000

d)

Aggregated information

- Aggregated volume

- Price

 

N/A (Single transaction)

e)

Date of the transaction

5 January 2018

f)

Place of the transaction

Outside a trading venue

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Miroslaw Izienicki

2

Reason for the notification

a)

Position/status

Non-executive Director and PDMR

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Amphion Innovations plc

b)

LEI

213800M7MTE2W2P6C104

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Options to acquire Ordinary Shares

b)

Nature of the transaction

Grant of options to acquire Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

1.94p

375,000

d)

Aggregated information

- Aggregated volume

- Price

 

N/A (Single transaction)

e)

Date of the transaction

5 January 2018

f)

Place of the transaction

Outside a trading venue

 

For further information please contact:

 

Amphion Innovations

Tel: +1 (212) 210 6224

Charlie Morgan

Panmure Gordon (UK) Limited (Nominated Adviser and Corporate Broker)

Tel: +44 (0)20 7886 2500

Freddy Crossley / Ryan McCarthy (Corporate Finance)

Charlie Leigh-Pemberton (Corporate Broking)

Northland Capital Partners Limited (Joint Corporate Broker)

Tel: +44 (0)20 3861 6625

Patrick Claridge / David Hignell (Corporate Finance)

John Howes (Corporate Broking)

Walbrook PR

Tel: +44 (0)20 7933 8780 or

Anna Dunphy / Paul McManus

amphion@walbrookpr.com

 

About Amphion Innovations plc

Amphion Innovations is a developer of medical, life science and technology businesses. We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in 7 Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies. The Partner Companies collectively own or control over 200 separately identified pieces of intellectual property, a number which grows rapidly each year.

 

On the web: www.amphionplc.com 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHDBLFFVFFBBBV
Date   Source Headline
31st Dec 20191:15 pmRNSAmphion Innovations
31st Dec 201912:36 pmRNSCancellation of trading on AIM
20th Nov 20197:00 amRNSDirectors' Dealings and Business Update
18th Oct 20197:00 amRNSSettlement of loan facility
11th Oct 20197:01 amRNSPolarean notes statement from Amphion Innovations
11th Oct 20197:00 amRNSSale of Partner Company Shares
3rd Oct 20197:00 amRNSSale of Partner Company Shares
25th Sep 20197:00 amRNSAmended Terms on Loan Facility
10th Sep 20194:56 pmRNSSale of Partner Company Shares
9th Aug 20194:14 pmRNSStatement on Amphion Innovations
9th Aug 20194:14 pmRNSDirectorate Change
9th Aug 20193:51 pmRNSSale of Partner Company Shares
1st Jul 20197:30 amRNSSuspension - Amphion Innovations Plc
27th Jun 20193:00 pmRNSAnnual Report and Accounts Update
14th Jun 20199:04 amRNSHolding(s) in Company
12th Jun 20197:00 amRNSLoan facility update
31st May 201910:28 amRNSHolding(s) in Company
20th May 20196:14 pmRNSHolding(s) in Company
1st Apr 20194:40 pmRNSSecond Price Monitoring Extn
1st Apr 20194:35 pmRNSPrice Monitoring Extension
1st Apr 20197:00 amRNSUpdate on Loan Facility
20th Mar 20197:00 amRNSHolding(s) in Company
19th Mar 20192:33 pmRNSSale of Partner Company Shares
18th Mar 20192:00 pmRNSPrice Monitoring Extension
15th Mar 20197:01 amRNSHolding(s) in Company
15th Mar 20197:00 amRNSSale of Partner Company Shares
11th Mar 20194:41 pmRNSAmended Terms on Loan Facility
26th Feb 20197:00 amRNSConvertible Promissory Note Extended
14th Feb 20198:00 amRNSStatement re. Motif Bio plc
7th Feb 20199:40 amRNSStmnt re Share Price Movement
1st Feb 20197:00 amRNSAppointment of Joint Broker
21st Jan 20197:00 amRNSWellGen Finalises License Agreement
11th Dec 20187:05 amRNSInvestment in Polarean & Loan Facility Repayment
16th Oct 20187:00 amRNSExtended Repayment and Draw Down on Loan Facility
28th Sep 20187:00 amRNSHalf-year Report
5th Sep 20187:00 amRNSBoard Change
23rd Aug 20183:20 pmRNSPolarean update
21st Aug 20187:15 amRNSMotif Bio notes statement from Amphion Innovations
21st Aug 20187:00 amRNSSale of Partner Company Shares
1st Aug 20184:47 pmRNSResult of AGM
29th Jun 20187:00 amRNSDirectorate Change
26th Jun 20187:00 amRNSFinal Results
23rd May 20187:00 amRNSMotif Bio notes statement from Amphion Innovations
23rd May 20187:00 amRNSSale of Partner Company Shares
20th Apr 20187:00 amRNSDirectorate Change
29th Mar 20187:00 amRNSAIM Admission & First Day of Dealings
29th Mar 20187:00 amRNSUpdate on Polarean Imaging IPO
26th Mar 20187:31 amRNSUpdate on Polarean Imaging proposed AIM IPO
2nd Mar 20187:00 amRNSConvertible promissory note extended to December
10th Jan 20185:09 pmRNSDirector dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.